measured by better responses, coupled with an understanding of where novel combinations work, and importantly, where and why they do not work. Identifying predictive biomarkers will help us better select therapies for individual patients and understanding mechanisms of resistance will inform successive combination studies. Whether or not everolimus becomes an important drug in our treatment of TCL remains to be seen and will no doubt be the subject of future studies. However, identifying new effective therapies in TCL with testable mechanisms of action and resistance, and designing rational combinations based on those results, may allow us to understand predictors of response or modes of resistance, will certainly elevate the quality of our clinical trials, and hopefully will move the field forward at an accelerated rate.
Conflict-of-interest disclosure: S.M.H. is supported by Spectrum, Seattle Genetics, Millennium, and Celgene for consultancy work; and A.J.M. is supported by Seattle Genetics and Merck for the same. n Dengue virus pirates human platelets Although binding of dengue to the dendritic cell-specific intracellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) has been implicated in platelet activation, apoptosis, and IL-1b synthesis, the authors substantiate that dengue directly binds DC-SIGN on the surface of platelets. Binding of dengue to DC-SIGN, however, also requires heparin sulfate proteoglycan and is significantly enhanced by thrombin. The DENV readily binds platelets at 37°C, but binding is also observed at room temperature (25°C). Interestingly, the authors found that trypsinization did not remove all of the surface-bound DENV. This finding suggested that DENV may be internalized, initiating a search for replication of the virus in platelets.
Although there was no prior evidence that platelets replicate DENV, the virus has been detected in platelets isolated from dengue patients. 5 Based on these findings and previous studies demonstrating that anucleate platelets are capable of translating their own messenger RNA, 6 the authors postulated that the DENV could replicate its viral RNA by usurping the translational machinery of platelets. DENV is a positive-sense (1) single-stranded RNA (ssRNA) with a genome of ;11 kb. 7 The dengue genome encodes a polyprotein precursor that is cleaved to 3 structural proteins (a core protein, membrane-associated protein, and envelope protein) and 7 nonstructural (NS) proteins. The authors show that platelets synthesize NS1 protein and replicate the dengue viral genome. Intact platelets, but not damaged platelets (ie, freeze-thawed), were capable of replicating all 4 serotypes of dengue and as predicted, the authors' studies revealed that platelets facilitate the generation of infectious DENV progeny. Production of infectious virus also indicates that platelets use functional Golgi components for nucleocapsid assembly and formation of virions. This story has several implications. First and foremost, it provides compelling evidence that dengue replication occurs in platelets (see figure) and raises the possibility that other (1)ssRNA viruses may be similarly propagated by these anucleate cytoplasts. Although platelets are in a prime position to defend against blood-borne viruses, it appears that dengue takes advantage of this frontline positioning to board platelets and swipe their translational cargo as a mode of survival. Second, de novo synthesis of NS1 may have implications beyond its primary role in dengue replication. NS1 is reported to be released into the plasma, where it is highly immunogenic, 8 and antiplatelet autoantibodies elicited by DENV NS1 induce thrombocytopenia in mice. 9 Thus, it is conceivable that production of viral antigens may impact platelet clearance by immune complex formation. Finally, the findings by Simon et al provide important new insights relevant to human DENV infection and platelet transfusion practices. Previously, DENV-induced synthesis and release of IL-1b in platelet-derived microparticles have been linked to injurious systemic inflammatory response syndromes and increased vascular permeability. 4 As DENV is now shown to commandeer human platelets, DENV may also use platelets to ship newly formed virions throughout the circulation and thus extend its infectious reach. Whether the thrombocytopenia that commonly occurs during dengue infection is a host-defense mechanism to limit viral dissemination remains to be determined. In addition, in the current report, DENV binding and replication in platelets occurred at 25°C, the temperature at which platelet concentrates are commonly stored prior to transfusion into recipient patients. As DENV infection may not always result in clinical symptoms, platelet concentrates collected from asymptomatic DENV-infected donors may serve as a reservoir for DENV transmission during platelet transfusions, especially in tropical or subtropical climates where DENV is endemic. As pirates say, "batten down the hatches." The elegant studies by Simon and cohorts suggest new and potentially hostile roles for human platelets when they are boarded and seized by DENV. "Shiver me timbers…."
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